Atherosclerotic cardiovascular disease remains a leading cause of death globally despite the existence of numerous cholesterol-lowering medications. While millions of adults manage their cardiovascular health through daily statins or monthly injections, the reality is that long-term patient compliance is often poor. When patients stop taking their medication, the benefit of lowering low-density lipoprotein, or LDL, is lost. Scribe Therapeutics aims to change this approach with STX-1150, a potential one-time epigenetic therapy.
Unlike traditional gene editing that cuts DNA, Scribe utilizes a nuclease-dead CasX protein to silence the PCSK9 gene epigenetically. By attaching a methyltransferase domain to this protein, the system can target specific sites and inhibit gene expression without causing permanent DNA breaks. This methodology avoids the risks associated with mutagenic damage. To further improve safety, researchers integrated an allosteric regulatory domain that keeps the enzyme inactive until it reaches the correct chromatin environment. This ensures the therapy only modifies the intended target.
Clinical trials are set to begin following regulatory clearance from the Australian Therapeutic Goods Administration. The goal is to provide a long-lasting alternative that removes the burden of daily or monthly dosing for the general population. While previous genetic therapies focused on rare, single-gene diseases, this approach targets a common condition influenced by complex genetic and lifestyle factors. By mimicking the genetic resistance naturally found in some individuals, the company hopes to offer a permanent solution to high cholesterol levels.
Delivery remains a technical hurdle, as the therapy uses lipid nanoparticles to transport RNA to the liver. These delivery vehicles have caused liver toxicity in other clinical applications, prompting Scribe to focus on dosage efficiency and specific formulations to minimize off-target effects. If the upcoming trials prove the therapy is safe and effective, it may offer a path for millions of people to manage cardiovascular risk without the side effects and lifestyle interruptions associated with current medical standards.